Armata Pharmaceuticals, Inc. (ARMP)
ARMP moved a median of -0.00% 30 minutes after news, and -1.02% by the close. How ARMP actually reacts to news — the realized, point-in-time move the market made, measured across 172 labeled events over the last three years with zero look-ahead.
ARMP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 19% | 128 |
| 30-min | -0.00% | 35% | 150 |
| 60-min | -1.00% | 37% | 153 |
| to close | -1.02% | 41% | 169 |
| Middle 50% of ARMP reactions | -3.54% to +1.05% |
|---|---|
| Median reaction (30-min) | -0.00% |
| Measured reactions | 172 |
Half of all Armata Pharmaceuticals, Inc. news events land between -3.54% and +1.05% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ARMP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ARMP's baseline. Nothing else.
Recent ARMP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States | Press release | PR Newswire | -2.87% | -0.52% | |
| Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development | Press release | PR Newswire | -4.79% | -13.33% | |
| Form 8-K Armata Pharmaceuticals, For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | -4.79% | -13.33% | |
| Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates | Press release | PR Newswire | +0.47% | +0.47% | |
| Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 | Press release | PR Newswire | -2.92% | -10.05% | |
| Form 8-K Armata Pharmaceuticals, For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -2.92% | -10.05% | |
| Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Press release | PR Newswire | +0.56% | -2.97% | |
| Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials | Press release | PR Newswire | -0.72% | -0.18% | |
| Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update | Press release | PR Newswire | +6.25% | +11.57% | |
| Form 10-Q Armata Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.25% | +11.57% | |
| Form 8-K Armata Pharmaceuticals, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +6.25% | +11.57% | |
| Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 | Press release | PR Newswire | +4.80% | +10.48% | |
| Form 8-K Armata Pharmaceuticals, For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | +4.80% | +10.48% | |
| Form 8-K Armata Pharmaceuticals, For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | +4.80% | +10.48% | |
| Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia | Press release | PR Newswire | -1.17% | -7.46% | |
| Form 8-K Armata Pharmaceuticals, For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | -1.17% | -7.46% | |
| Form S-8 Armata Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | -1.17% | -7.46% | |
| Form 8-K/A Armata Pharmaceuticals, For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | -2.04% | -11.56% | |
| Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 | Press release | PR Newswire | -2.11% | -3.31% | |
| Form 8-K Armata Pharmaceuticals, For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -2.11% | -3.31% | |
| Form 8-K Armata Pharmaceuticals, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.17% | |
| Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update | Press release | PR Newswire | -1.49% | -5.75% | |
| Form 10-Q Armata Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.49% | -5.75% | |
| Form 8-K Armata Pharmaceuticals, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -1.49% | -5.75% | |
| Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 | Press release | PR Newswire | -1.75% | -0.22% | |
| Form 8-K Armata Pharmaceuticals, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -1.75% | -0.22% | |
| Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" | Press release | PR Newswire | +8.67% | +10.92% | |
| Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors | Press release | PR Newswire | +2.15% | -12.49% | |
| Form 8-K Armata Pharmaceuticals, For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | +2.15% | -12.49% | |
| Form ARS Armata Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.37% | -13.86% | |
| Form DEF 14A Armata Pharmaceuticals, For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | +1.37% | -13.86% | |
| Form 8-K Armata Pharmaceuticals, For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +1.24% | +0.76% | |
| Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results | Press release | PR Newswire | +6.17% | +15.29% | |
| Form 10-K Armata Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +6.17% | +15.29% | |
| Form 8-K Armata Pharmaceuticals, For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | +6.17% | +15.29% | |
| Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update | Press release | PR Newswire | +0.00% | -0.60% | |
| Form 8-K Armata Pharmaceuticals, For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.60% | |
| Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02 | Press release | PR Newswire | -0.44% | +8.66% | |
| Form 8-K Armata Pharmaceuticals, For: Feb 23 | SEC filing · Form 8-K | SEC EDGAR | -0.44% | +8.66% | |
| Form 8-K Armata Pharmaceuticals, For: Jan 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.00% | |
| Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus | Press release | PR Newswire | -5.62% | -3.64% | |
| Form 8-K Armata Pharmaceuticals, For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | -5.62% | -3.64% | |
| Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST | Press release | PR Newswire | -0.76% | +4.56% | |
| Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update | Press release | PR Newswire | -0.36% | — | |
| Form 10-Q Armata Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.36% | — | |
| Form 8-K Armata Pharmaceuticals, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | — | |
| Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California | Press release | PR Newswire | +4.24% | +3.33% | |
| Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™ | Press release | PR Newswire | — | +101.93% | |
| Form 8-K Armata Pharmaceuticals, For: Oct 22 | SEC filing · Form 8-K | SEC EDGAR | — | +101.93% | |
| Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™ | Press release | PR Newswire | +0.00% | -1.21% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ARMP section they belong to.
Where else ARMP is measured.
ARMP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Armata Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled ARMP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 172 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 35% of ARMP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ARMP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.